About Participation in the Open Label Extension Study

Participating in the Open Label Extension

Upon completion of either ACT-AD or LIFT-AD study, interested participants are eligible to enroll in the Open Label Extension study of ATH-1017. This study provides an opportunity for interested participants to receive the active drug during this study. Active participants in the OLEX Study will remain blinded to their randomized study drug assignment in either the ACT-AD or LIFT-AD trial. The dosing schedule is the same as in ACT-AD or LIFT-AD. Participation in the study takes about eight months including approximately six months of treatment duration.

OLEX Feeding Graphic-01

What is Involved in the Trials?

Contact your study site for more information.